. Dans-notre-Étude, on constatait que : -94,4% des patients avaient au moins un effet indésirable. Seuls deux patients ont été indemnes d'effets indésirables

. Dans-les-essais-thérapeutiques, l'incidence d'une anémie se majorait de 20% (50% pour le bocéprévir et 40% pour le télaprévir), ainsi que la sévérité (49). Cependant, dans notre cohorte, le taux d'anémie était de 30% avec un taux moyen similaire de 10

F. Negro and A. Alberti, The global health burden of hepatitis C virus infection, Liver International, vol.31, issue.(Suppl. 2), 2011.
DOI : 10.1111/j.1478-3231.2011.02537.x

V. Mallet, H. Gilgenkrantz, J. Serpaggi, V. Verkarre, A. Vallet-pichard et al., Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C, Annals of Internal Medicine, vol.149, issue.6, pp.399-403, 2008.
DOI : 10.7326/0003-4819-149-6-200809160-00006

M. Bourlière, A. Khaloun, C. Wartelle-bladou, V. Oules, I. Portal et al., Future treatment of patients with HCV cirrhosis, Liver International, vol.54, issue.suppl, pp.113-119, 2012.
DOI : 10.1111/j.1478-3231.2011.02702.x

S. Deuffic-burban, P. Mathurin, S. Pol, C. Larsen, F. Roudot-thoraval et al., Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis, Gut, vol.61, issue.2, pp.290-296, 2012.
DOI : 10.1136/gutjnl-2011-300586

A. Pariente, P. Lahmek, C. Duprat, J. Denis, R. Faroux et al., Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ???true life???, European Journal of Gastroenterology & Hepatology, vol.22, issue.11, pp.1297-1302, 2010.
DOI : 10.1097/MEG.0b013e32833bb4b0

C. Hézode, C. Dorival, D. Lucidarme, T. Dao, P. Cacoub et al., Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) ??? NCT01514890, Journal of Hepatology, vol.59, issue.3, pp.434-475, 2013.
DOI : 10.1016/j.jhep.2013.04.035

C. Larsen, C. Pioche, C. Brouard, M. Jauffret-roustide, J. Pillonel et al., Épidémiologie de l'infection par le virus de l'hépatite C en France, Hépato-Gastro, vol.19, issue.8, pp.635-640, 2012.

C. Payan, Du virus à l'histoire naturelle de l'hépatite C. Hépato-Gastro, pp.641-648, 2012.

N. Carre and P. Joret, Hépatite C chronique: apport des antiprotéases, télaprévir et bocéprévir, Dossier du CNHIM, vol.1, pp.7-66, 2013.

V. Leroy, L. Serfaty, M. Bourlière, J. Bronowicki, P. Delasalle et al., Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver, Liver International, vol.56, issue.17, pp.1477-1492, 2012.
DOI : 10.1111/j.1478-3231.2012.02856.x

A. Cahour, A new challenge for the HCV research, Virologie, vol.10, pp.159-165, 2006.

D. Moradpour, F. Penin, and C. Rice, Replication of hepatitis C virus, Nature Reviews Microbiology, vol.281, issue.6, pp.453-463, 2007.
DOI : 10.1038/nrmicro1645

URL : https://hal.archives-ouvertes.fr/hal-00313684

G. Pialoux, Hépatite C : un pas vers l'éradication ? [en ligne]

M. Bourlière, Les nouvelles molécules à l'EASL [en ligne], 2013.

E. Gane, C. Stedman, R. Hyland, X. Ding, E. Svarovskaia et al., Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C, New England Journal of Medicine, vol.368, issue.1, pp.34-44, 2013.
DOI : 10.1056/NEJMoa1208953

K. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M. Davis et al., Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.381, issue.9883, pp.2100-2107, 2013.
DOI : 10.1016/S0140-6736(13)60247-0

E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-torres, T. Hassanein et al., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-1887, 2013.
DOI : 10.1056/NEJMoa1214853

. Sofosbuvir, GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial, J Hepatol, vol.58, pp.663-668, 2013.

I. Jacobson, S. Gordon, K. Kowdley, E. Yoshida, M. Rodriguez-torres et al., Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options, New England Journal of Medicine, vol.368, issue.20, pp.1867-1877, 2013.
DOI : 10.1056/NEJMoa1214854

S. Zeuzem, V. Soriano, T. Asselah, J. Bronowicki, A. Lohse et al., Faldaprevir and Deleobuvir for HCV Genotype 1 Infection, New England Journal of Medicine, vol.369, issue.7, pp.630-639, 2013.
DOI : 10.1056/NEJMoa1213557

E. Rosenthal, 1 en échec de trithérapie par télaprévir ou bocéprévir avec une association orale par daclatasvir, sofosbuvir avec ou sans ribavirine [en ligne100-de-reponse-virologique- soutenue-chez-des-patients-g-1-en-echec-de-tritherapie-par-telaprevir-ou-boceprevir-avec-une- association-orale-par-daclatasvir-sofosbuvir-avec-ou-sans-ribavirine, 1499.

M. Shiffman, C. Morishima, J. Dienstag, K. Lindsay, J. Hoefs et al., Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial, Gastroenterology, vol.137, issue.6, 1986.
DOI : 10.1053/j.gastro.2009.08.067

C. Hézode, L. Castéra, F. Roudot-thoraval, M. Bouvier-alias, I. Rosa et al., Liver stiffness diminishes with antiviral response in chronic hepatitis C, Alimentary Pharmacology & Therapeutics, vol.42, issue.6, pp.656-663, 2011.
DOI : 10.1111/j.1365-2036.2011.04765.x

A. Conférence-de-consensus, Traitement de l'hépatite C. [en ligne], 2002.

J. Mchutchison, E. Lawitz, M. Shiffman, A. Muir, G. Galler et al., Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-593, 2009.
DOI : 10.1056/NEJMoa0808010

T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg et al., Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy, Gastroenterology, vol.136, issue.5, pp.1618-1628, 2009.
DOI : 10.1053/j.gastro.2009.01.039

C. Hézode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol et al., Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-1850, 2009.
DOI : 10.1056/NEJMoa0807650

J. Mchutchison, M. Manns, A. Muir, N. Terrault, I. Jacobson et al., Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-1303, 2010.
DOI : 10.1056/NEJMoa0908014

P. Kwo, E. Lawitz, J. Mccone, E. Schiff, J. Vierling et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.376, issue.9742, pp.705-716, 2010.
DOI : 10.1016/S0140-6736(10)60934-8

F. Poordad, J. Mccone, . Jr, B. Bacon, S. Bruno et al., Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011.
DOI : 10.1056/NEJMoa1010494

URL : https://hal.archives-ouvertes.fr/hal-00867494

S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago et al., Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2428, 2011.
DOI : 10.1056/NEJMoa1013086

K. Sherman, S. Flamm, N. Afdhal, D. Nelson, M. Sulkowski et al., Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection, New England Journal of Medicine, vol.365, issue.11, pp.1014-1024, 2011.
DOI : 10.1056/NEJMoa1014463

B. Bacon, S. Gordon, E. Lawitz, P. Marcellin, J. Vierling et al., Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1217, 2011.
DOI : 10.1056/NEJMoa1009482

H. Fontaine, Organisation du traitement antiviral C et effets secondaires, Hépato-Gastro, vol.19, pp.661-667, 2012.

D. Saadoun, A. Delluc, J. Piette, and P. Cacoub, Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis, Current Opinion in Internal Medicine, vol.7, issue.2, pp.23-28, 2008.
DOI : 10.1097/BOR.0b013e3282f1330c

URL : https://hal.archives-ouvertes.fr/hal-00684157

A. Thompson, A. Muir, M. Sulkowski, D. Ge, J. Fellay et al., Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus, Gastroenterology, vol.139, issue.1, pp.120-129, 2010.
DOI : 10.1053/j.gastro.2010.04.013

H. Fontaine, Traitement de l'hépatite chronique virale C : infection par un génotype non 1, Hépato- Gastro, vol.19, pp.683-686, 2012.

A. Pascale and L. Serfaty, Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?, Journal of Hepatology, vol.58, issue.2, pp.391-394, 2013.
DOI : 10.1016/j.jhep.2012.09.023

M. Martinot-peignoux, C. Stern, S. Maylin, M. Ripault, N. Boyer et al., Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin, Hepatology, vol.14, issue.4, pp.1122-1126, 2010.
DOI : 10.1002/hep.23444

C. Niederau, D. Hüppe, E. Zehnter, B. Möller, R. Heyne et al., Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice, World Journal of Gastroenterology, vol.18, issue.12, pp.1339-1347, 2012.
DOI : 10.3748/wjg.v18.i12.1339

E. Chen, S. Sclair, F. Czul, B. Apica, P. Dubin et al., A Small Percentage of Patients With Hepatitis C Receive Triple Therapy With Boceprevir or Telaprevir, Clinical Gastroenterology and Hepatology, vol.11, issue.8, pp.1014-1020, 2013.
DOI : 10.1016/j.cgh.2013.03.032

J. Holmes, P. Desmond, and A. Thompson, Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?, Journal of Viral Hepatitis, vol.364, issue.Suppl. 4, pp.677-684, 2012.
DOI : 10.1111/jvh.12003

D. Jensen and S. Pol, IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?, Liver International, vol.54, issue.Suppl. 1, pp.74-78, 2012.
DOI : 10.1111/j.1478-3231.2011.02712.x

M. Bourlière, D. Ouzan, M. Rosenheim, M. Doffoël, P. Marcellin et al., Pegylated interferon-??2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003???2007), Antiviral Therapy, vol.17, issue.1, pp.101-110, 2003.
DOI : 10.3851/IMP1935

S. Pol, V. Thiers, J. Nousbaum, C. Legendre, P. Berthelot et al., The changing relative prevalence of hepatitis C virus genotypes: Evidence in hemodialyzed patients and kidney recipients, Gastroenterology, vol.108, issue.2, pp.581-583, 1995.
DOI : 10.1016/0016-5085(95)90088-8

C. Hézode, Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice, Liver International, vol.31, issue.Suppl. 1, pp.32-38, 2012.
DOI : 10.1111/j.1478-3231.2011.02707.x

H. Fontaine and . Cupic, efficacité et tolérance 12 semaines après l'arrêt de la trithérapie. [en ligne]cupic-efficacite-et-tolerance-12-semaines- apres-l-arret-de-la-tritherapie, 1461.

M. Manns, J. Mchutchison, S. Gordon, V. Rustgi, M. Shiffman et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-965, 2001.
DOI : 10.1016/S0140-6736(01)06102-5

C. Hézode, SVR 12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC)

F. Poordad, E. Lawitz, K. Reddy, N. Afdhal, C. Hézode et al., Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial, Gastroenterology, pp.16-5085, 2013.